IDEAYA Biosciences Announces Submission of IND Application for Development Candidate MAT2A IDE397 to US FDA

0

IDE397 is under development as a potential best-in-class MAT2A inhibitor for the suppression of MTAP, which is prevalent in approximately 15% of all solid tumors

Program update IDE397 to be presented at JP Morgan’s 39th Annual Healthcare Conference, including preclinical data showing tumor regressions in MTAP suppressed PDX models and proposed Phase 1 clinical plan

SOUTH SAN FRANCISCO, California, January 11, 2021 / PRNewswire / – IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapies, today announced that it has re-applied investigational drug (IND) with the US Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to evaluate IDE397, a small molecule methionine adenosyltransferase 2a (MAT2A) inhibitor treatment of patients with solid tumors with methylthioadenosine phosphorylase (MTAP) deletion.

(PRNewsfoto / IDEAYA Biosciences, Inc.)

“The submission of IDE397 IND is an important milestone for IDEAYA as we advance our broader synthetic lethality pipeline of potential first-class therapies. IDE397 was discovered through our efforts to develop a potential first-order MAT2A inhibitor, and we have our target product profile, ”said Michael Dillon, Ph.D., Scientific Director of IDEAYA Biosciences. “IDE397 is highly selective and active in suppressing MTAP, which accounts for approximately 15% of all solid tumors, and we are excited about the potential impact that IDE397 may have for these patients,” said Yujiro S. Hata, Chairman and CEO, IDEAYA Biosciences.

IDEAYA Biosciences will present a program update on IDE397 and its broader synthetic lethality pipeline at 39e JP Morgan Annual Healthcare Conference. The presentation will include preclinical data demonstrating tumor regressions in IDE397 monotherapy in PDX models with MTAP suppression on several types of solid tumors. IDEAYA will also present its draft IDE397 Phase 1 clinical plan in MTAP-deleted solid tumors, including monotherapy and combination strategies, and discuss the rationale for combining IDE397 and the PRMT inhibitor of GSK type I GSK3368715.

Presentation of IDEAYA for the 39e The JP Morgan Healthcare Annual Conference is available at https://ir.ideayabio.com/.

About IDEAYA Biosciences
IDEAYA is an oncology-focused precision medicine company engaged in the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. IDEAYA’s approach integrates the ability to identify and validate translational biomarkers with drug discovery to select the patient populations most likely to benefit from its targeted therapies. IDEAYA applies its early research and drug discovery capabilities to synthetic lethality, which represents an emerging class of precision medicine targets.

Forward-looking statements
This press release contains forward-looking statements, including, but not limited to, the potential impact of IDE397. These forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA’s preclinical and clinical development programs, results, performance or future achievements to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the initial stage of development of IDEAYA programs, the process of designing and conducting preclinical and clinical trials, the approval processes. regulatory, the timing of regulatory filings, the challenges associated with manufacturing pharmaceuticals, the ability of IDEAYA to successfully establish, protect and defend its intellectual property, the effects on IDEAYA’s business from the global COVID pandemic -19, and other matters that could affect the sufficiency of existing liquidity to fund operations. IDEAYA assumes no obligation to update or revise any forward-looking statements. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with IDEAYA’s business in general, see IDEAYA’s recent quarterly report on form 10-Q filed at November 12, 2020 and any current and periodic report filed with the United States Securities and Exchange Commission.

Cision

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-announces-submission-of-ind-application-for-mat2a-development-candidate-ide397-with-the-us-fda-301204730.html

SOURCE IDEAYA Biosciences, Inc.

Share.

Comments are closed.